Overview of EMA-defined biosimilars, EU IP protections and limits including Bolar exemption, SPC manufacturing waiver, skinny labelling and loss of exclusivity strategies.
We reflect on a year of life sciences innovation, highlighting Clarivate’s Drugs to Watch 2025, emerging therapy trends, AI-driven R&D and the evolving patent strategies shaping the sector.
Microbes are ubiquitous here on Earth and can survive a range of environmental conditions encompassing broad ranges of temperature, pH, salinity, energy,
Today is the UN’s International Day of Women and Girls in Science. It’s fair to say that, in modern science, we stand
Welcome to 2025 – the ‘International Year of Quantum Science and Technology’ – but what are Quantum Technologies? Welcome to 2025! This
Do you have an interest in mRNA technologies, in particular mRNA vaccines? The European Patent Office (EPO) has published an insight report
Following the UK’s exit from the European Union (EU), Retained EU Plant Variety Rights were awarded to provide continuing protection in the
On 27 April 2023 the European Commission published proposals concerning supplementary protection certificates (SPCs) for medicinal products and plant protection products. SPC protection
The Enlarged Board of Appeal of the European Patent Office issued the decision in referral G2/21 on 23 March 2023. This referral concerned the admissibility of post-published evidence in the assessment of inventive step.
The European Patent Office (EPO) has recently ruled that patients in a clinical trial were not members of the public such that
